The clock is ticking on key decisions related to a pair of drugs for myelodysplastic syndrome (MDS) - MGI Pharma Inc.'s Dacogen and Celgene Corp.'s Revlimid - and the market seems ready to widen, even as physicians continue to look fondly upon Pharmion Corp.'s injectable Vidaza (azacitidine), the compound in-licensed from Pharmacia & Upjohn Co., now part of Pfizer Inc. Read More